Namalela Tozé, Moi Flavia, Dipuve Amélia, Pota Pedro Marizane, Guambe José, Couto Maria Tereza, Boonstoppel Laura
Thinkwell, Maputo, Mozambique.
Thinkwell, Geneva, Switzerland.
BMC Health Serv Res. 2025 Apr 9;25(1):521. doi: 10.1186/s12913-025-12671-3.
Vaccines were a key tool in controlling the COVID-19 pandemic. However, the cost of delivering these vaccines in low- and middle-income countries was highly uncertain, due to the unprecedented delivery volume and the need to reach new target populations. To fill this evidence gap, this study estimates the cost of delivering COVID-19 vaccines in Mozambique.
This retrospective, bottom-up costing study estimated the financial and economic costs of delivering COVID-19 vaccines in 2022 USD, during the first year of introduction. Recurrent costs were collected for the initial rollout period (March 8th to April 8th 2021) and for a later, higher-volume period (December 1st 2021 to February 28th 2022). The study was conducted from a payer perspective. Data was collected at health facilities from a purposively selected sample of 27 vaccination sites, as well as from 6 district and provincial health offices in 2 provinces, the Ministry of Health, and development partners. The overall cost per dose was obtained by estimating and aggregating the volume-weighted average cost per dose for each administrative level. Qualitative interviews were also conducted to contextualize cost findings.
The cost per dose for the first year of implementation was $1.14 for economic costs and $0.50 for financial costs. For the initial rollout period, when the volume delivered was low (64 doses/vaccination day on average), the economic cost per dose was $3.56 and decreased considerably to $0.85 when the program delivered at scale and volume delivered increased to 225 doses/vaccination day. Opportunity costs made up a considerable share of the economic cost per dose, 73% and 49% respectively during the initial rollout and when the program delivered at scale. The qualitative interviews found that political prioritization and workers' commitment made the program possible despite little financial investment.
The cost of delivering COVID-19 vaccines in Mozambique was found to be low compared to other countries, due to heavy reliance on existing resources and little additional investment into the program. Findings from this study can support the government in planning and budgeting for the future of the COVID-19 vaccination program as well as other vaccination efforts.
疫苗是控制新冠疫情的关键工具。然而,由于史无前例的疫苗交付量以及需要覆盖新的目标人群,在低收入和中等收入国家交付这些疫苗的成本极不确定。为填补这一证据空白,本研究估算了莫桑比克新冠疫苗的交付成本。
这项回顾性、自下而上的成本核算研究以2022年美元估算了在引入疫苗的第一年交付新冠疫苗的财务成本和经济成本。收集了初始推广阶段(2021年3月8日至4月8日)以及随后更高交付量阶段(2021年12月1日至2022年2月28日)的经常性成本。该研究从付款方角度进行。数据是在医疗机构从27个疫苗接种点的目标选定样本以及来自2个省份的6个地区和省级卫生办公室、卫生部和发展伙伴处收集的。通过估算和汇总每个行政层面每剂疫苗的体积加权平均成本得出每剂疫苗的总成本。还进行了定性访谈以阐述成本调查结果。
实施第一年每剂疫苗的经济成本为1.14美元,财务成本为0.50美元。在初始推广阶段,疫苗交付量较低(平均每天64剂)时,每剂疫苗的经济成本为3.56美元,当项目大规模交付且交付量增加到每天225剂时,成本大幅降至0.85美元。机会成本在每剂疫苗的经济成本中占相当大的比例,在初始推广阶段和项目大规模交付阶段分别占73%和49%。定性访谈发现,尽管资金投入很少,但政治上的优先安排和工作人员的奉献使该项目得以实施。
由于严重依赖现有资源且对该项目几乎没有额外投资,与其他国家相比,莫桑比克新冠疫苗的交付成本较低。本研究结果可为政府规划和预算新冠疫苗接种项目的未来以及其他疫苗接种工作提供支持。